Journal Mobile Options
Table of Contents
35, No. 5, 2012
Issue release date: May 2012
Onkologie 2012;35:293–299
(DOI:10.1159/000338529)
Review Article · Übersichtsarbeit

First-Line Therapy of Mutated Non-Small Cell Lung Cancer: An Update

Stöhlmacher-Williams J.
Medizinische Klinik und Poliklinik I, Dresden, Germany

Abstract

Currently, many treatment options and new targets for cancer therapies for patients with advanced non-small cell lung cancer (NSCLC) are being evaluated. This article discusses in detail the significance of first-line and second-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and inhibitors of the vascular endothelial growth factor receptor (VEGFR) and EML4-ALK. Furthermore, the article summarizes the implications and future prospects of using molecular testing in the field of NSCLC with focus on EGFR mutations, KRAS mutation, EML4-ALK fusion gene detection, and EGFR expression.

 goto top of outline Author Contacts

PD Dr. med. habil. J. Stöhlmacher-Williams, Medizinische Klinik und Poliklinik I, Fetscherstr. 74, 01307 Dresden, Germany, Tel. +49 351-458 2311, Fax -449 210 630, jan.stoehlmacher@uniklinikum-dresden.de


 goto top of outline Article Information

Published online: April 24, 2012
Number of Print Pages : 7


 goto top of outline Publication Details

Onkologie (International Journal for Cancer Research and Treatment)

Vol. 35, No. 5, Year 2012 (Cover Date: May 2012)

Journal Editor: Schmoll H.-J. (Halle/Saale), Hallek M. (Köln)
ISSN: 0378-584X (Print), eISSN: 1423-0240 (Online)

For additional information: http://www.karger.com/ONK


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.